Representing clinical trials — in vitro
We develop fully functional, accurate, and disease-representative human organoids using reprogrammed human cells.
Problems
More than 4.9 billion people live with some form of skin disease. Every year, hundreds of clinical trials and thousands of new cosmetics and clinical trials compete in a market that already exceeds $200 billion, yet few inventions reach consumers.
Without effective human preclinical models capable of demonstrating long-term efficacy and safety in human models, identifying molecules that work in people, not just animals, remains an expensive, slow, and risky process.
High costs and long deadlines:
Each approved drug carries the cost of 11 failed candidates. Thus, it takes 12 years and $700 million to develop a new skin drug.
Current models do not represent humans:
92% of molecules fail clinical trials, demonstrating that current preclinical models fail to represent humans
Why can't this wait?
Ethics:
More than 200 million animals are used every year in testing, even though they are not representative.
Global change:
Major economies have restricted or banned animal testing. Those arriving without alternatives will be priced out of the market.
Innovative Methods:
They have a short cultivation duration and low complexity, which does not allow for understanding the real effect or toxicity of the molecule on the skin.
Why this is
important?
Truly human preclinical platforms reduce clinical failures, eliminate billions in wasted capital, and make viable therapies for a variety of diseases with no current cure.
Where every 10 pp increase in clinical success rate saves $300 million per approved drug.
Complex, long-lasting skin models make this gain a reality and unlock a multi-billion dollar dermocosmetics and dermatology market.
Our approach
Machine
Learning
Organoids
Reprogramming
Cell
By combining our three pillars, we can replicate the self-renewal process that human skin naturally undergoes and thus build a genuine long-lasting model.
We develop cells that remain active in the basal layer, proliferate continuously and, as they differentiate and mature, replace the upper layers, faithfully recreating the skin's natural cycle.
With this, we deliver more predictive analyses on:
• Effectiveness
• Repeated dose toxicity
• High complexity models
Genetic Diversity
Advantages
Acne
Psoriasis
Warts
Melanoma
Eczema
Hives
Ringworm
Disease models
Athlete's Foot
Rosacea
Repeated dose efficacy and toxicity tests
Highly representative
Chronic assessment
Possibility
of customization
Our Team
Gabriel Lohn Costa (CEO)
(CEO)
Gabriel is an accountant, graduated from the University of Santa Catarina (UFSC), with 9 years of experience in business management, financial management and structuring investment fundraising.
He worked for 5 years as head of search and selection and portfolio manager in venture building and venture capital with a focus on biotechnology.
Viviana Costa Gagosia CSO
Viviana is a biologist and holds a master's degree in Genetics from the Federal University of Paraná (UFPR), a PhD candidate in Biosciences and Biotechnology at Fiocruz/PR, and completed a sandwich doctorate at the Instituto de Salud Carlos III, in Madrid, Spain.
Specialist in 2D and 3D cell culture and development of alternative methods. Awarded by PETA International Science Consortium Ltd. (2020) for the development of the reconstructed human epidermis (RHE) protocol for skin irritation testing.
%2016_52_07_5e8e245a.jpg)
Jordana Andrade Santos
Tissue Engineering
PhD in Pharmaceutical Sciences, with a degree in Biomedicine and a Master's in Physiological Sciences, passionate about the advancement of science and innovation.
Jordana has experience with biomaterials, tissue engineering, regenerative medicine, 3D culture, microphysiological systems and in vitro toxicology, always guided by the philosophy of science without animals.
Isabelle Zaboroski Silva
Cell reprogramming
Biotechnologist from PUCPR (2015), with a master's degree (2015) and a doctorate (2023) in the Biosciences and Biotechnology Program. Research fellow (2022–2023) at Case Western Reserve University, in Cleveland (USA).
Isabelle has experience with cellular reprogramming and rare genetic diseases. She serve as a scientific advisor to the CYFIP2 Network, an association of patients with CYFIP2 variants and their families.
Scientific Advisory Board
Edroaldo Lummertz da Rocha
He trained at prestigious institutions such as the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Mayo Clinic, Boston Children's Hospital, and Harvard Medical School. He is currently a professor at the Federal University of Santa Catarina (UFSC).
His research, at the convergence of biology, computational biology, and artificial intelligence, has advanced the fields of stem cell biology and engineering.
Daniela Morais Leme
She holds a bachelor's degree in Biological Sciences and a master's and doctorate in Cellular and Molecular Biology (UNESP). She completed a postdoctoral degree in in vitro toxicology, having received international awards in the areas of toxicology and sustainability. She is currently a professor in the Genetics Department at the Federal University of Paraná (UFPR) and coordinator of the In Vitro (Eco)Toxicology Laboratory, a laboratory associated with RENAMA.
Experience in new methodological approaches (NAMs) for chemical safety and sustainability, leading studies on the development and implementation of in vitro methods.
Partners
_edit.png){kind=logo}
